Geftistar 250mg Tablet

About

Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used in the treatment of non-small cell lung cancer (NSCLC). It specifically targets and inhibits the tyrosine kinase activity of the EGFR, which is often overexpressed or mutated in various cancers, leading to uncontrolled cell growth and proliferation. By blocking this signaling pathway, gefitinib helps to inhibit tumor growth, metastasis, and angiogenesis, and promotes apoptosis in cancer cells.

This medication is particularly effective in patients with NSCLC whose tumors have specific activating mutations in the EGFR gene, such as exon 19 deletions or L858R point mutations. It is administered orally and represents a targeted therapy approach, offering a more personalized treatment option compared to traditional chemotherapy. Patients undergoing gefitinib therapy require regular monitoring for adverse effects and assessment of treatment response.

Uses

• Non-small cell lung cancer (NSCLC) with EGFR mutations
• First-line treatment for advanced NSCLC
• Second-line treatment for advanced NSCLC
• Maintenance therapy for NSCLC

Directions For Use

Take orally as directed by your physician, usually once daily with or without food. Do not crush or chew the tablet.

Benefits

• Targeted therapy for EGFR-mutated NSCLC
• Oral administration for convenience
• Improves progression-free survival
• May improve overall survival in selected patients
• Generally well-tolerated compared to chemotherapy
• Reduces tumor size and disease progression

Side Effects

• Diarrhea
• Rash (acne-like)
• Dry skin
• Nausea
• Vomiting
• Anorexia
• Stomatitis
• Conjunctivitis
• Elevated liver enzymes
• Interstitial lung disease (rare but serious)
• Proteinuria
• Hair disorders

Safety Measures

• Alcohol - Moderate alcohol consumption is generally acceptable, but excessive intake may exacerbate liver side effects.
• Pregnancy - Gefitinib is not recommended during pregnancy due to potential fetal harm. Use effective contraception.
• Breastfeeding - Breastfeeding should be avoided during gefitinib treatment due to potential excretion into breast milk.
• Liver - Use with caution in patients with pre-existing liver impairment; monitor liver function closely.
• Kidney - No specific dose adjustment is typically required for mild to moderate renal impairment. Use with caution in severe cases.
• Lung - Monitor closely for signs of interstitial lung disease (ILD), a rare but serious side effect, especially in patients with pre-existing lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.